OBJECTIVE -C-reactive protein (CRP) independently predicts cardiovascular disease (CVD); whether it can stratify risk in those with metabolic syndrome and diabetes is not well documented. We evaluated whether elevated CRP levels modify the relationship of metabolic syndrome and diabetes with CVD in U.S. adults.
I
t is well known that C-reactive protein (CRP), a sensitive circulating marker of inflammation, is independently associated with increased risk of cardiovascular disease (CVD) (1) (2) (3) (4) (5) , with inflammation having a key role in the pathophysiology of atherosclerosis (6, 7) . Inflammation is also associated with metabolic syndrome and diabetes (8, 9) . Additionally, CRP is associated with insulin resistance (10, 11) . A recent statement from the Centers for Disease Control and Prevention and the American Heart Association considered the measurement of CRP for assessing the risk of CVD (12) . We examined the relationship of preexisting CVD with metabolic syndrome and diabetes stratified by CRP levels in a population-representative sample of U.S. adults and whether CRP levels would help to further stratify the likelihood of CVD in patients with diabetes or metabolic syndrome.
RESEARCH DESIGN AND
METHODS -In a cross-sectional study, we utilized data on 3,873 subjects (weighted to a U.S. population of 156 million) aged Ն18 years who were participants of the National Health and N u t r i t i o n E x a m i n a t i o n S u r v e y (NHANES) 1999 -2000, a multistage probability sample design survey. The study was approved by the institutional review board of the University of California, Irvine (IRB no. 2003-2884).
Serum triglyceride levels were measured enzymatically after hydrolyzation to glycerol on a Hitachi 704 analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN). HDL cholesterol was measured after the precipitation of other lipoproteins with a heparin-manganese chloride mixture on a Hitachi 704 analyzer. Plasma glucose concentration was measured using an enzymatic reaction (Cobas Mira Chemistry System; Roche Diagnostic Systems, Montclair, NJ). Highsensitivity CRP was analyzed by latexenhanced nephelometry. These assays are performed on a Behring Nephelometer for quantitative CRP determination. The lowest detection limit of 0.1 mg/l allowed for three categories of CRP levels, which reflect the Centers for Disease Control/ American Heart Association cut points of low CRP (Ͻ1 mg/l), intermediate CRP (1-3 mg/l), or high CRP (Ͼ3 mg/l) (12) .
Assessment of metabolic syndrome, diabetes, and CVD Metabolic syndrome was defined by modified National Cholesterol Education Program criteria (13) Those reporting a prior myocardial infarction, stroke, or heart failure were classified as having CVD.
Statistical analyses
The 2 test of proportions, weighted to the U.S. population using NHANES 1999 -2000 sample weights, was used to compare the prevalence of the individual baseline characteristics across clinical conditions. Multivariable logistic regressions, weighted to the U.S. population, were performed to examine the odds of CVD in those with metabolic syndrome or diabetes compared with those free of these conditions, stratified by the CRP levels as defined above. Analyses, completed using the SUDAAN PROC RLO-GIST procedure (providing odds ratios [ORs] and 95% CIs), were adjusted for age, sex, total cholesterol, and cigarette smoking (risk factors not comprising the definition for metabolic syndrome). As a result, subjects were categorized into nine groups: 1) no metabolic syndrome/ diabetes and low CRP (referent), 2) no metabolic syndrome/diabetes and intermediate CRP, 3) no metabolic syndrome/ diabetes and high CRP, 4) metabolic syndrome and low CRP, 5) metabolic syndrome and intermediate CRP, 6) metabolic syndrome and high CRP, 7) diabetes and low CRP, 8) diabetes and intermediate CRP, and 9) diabetes and high CRP. In a separate model, we examined the association of CRP with CVD, controlling for age, sex, total cholesterol, cigarette smoking, metabolic syndrome, and diabetes as covariates. Statistical procedures were done using SAS version 8.1 (SAS Institute, Cary, NC), and procedures using sample weights for projection to the U.S. 
RESULTS

Baseline characteristics
There were significant differences between disease groups in mean age, waist circumference, total cholesterol, HDL, LDL, triglycerides, blood glucose, blood pressure, CRP, and smoking (Table 1) . Mean systolic and diastolic blood pressure, total cholesterol, and LDL were highest and HDL was lowest in those with metabolic syndrome compared with those with neither metabolic syndrome nor diabetes (P Ͻ 0.001). The remaining metabolic risk factors were highest in those with diabetes compared with those with neither metabolic syndrome nor diabetes (P Ͻ 0.001). In addition, those with diabetes had higher triglycerides (P Ͻ 0.01), blood glucose (P Ͻ 0.001), and CRP (P Ͻ 0.01) than those with metabolic syndrome and had lower total cholesterol (P Ͻ 0.05), HDL (P Ͻ 0.01), LDL (P Ͻ 0.001), and diastolic blood pressure (P Ͻ 0.001) compared with those with metabolic syndrome. Risk of CVD for those with metabolic syndrome and diabetes, stratified by CRP From multiple logistic regression, the adjusted OR for CVD for those with no disease and high CRP levels was 1.99 (95% CI 1.10 -3.59; P Ͻ 0.05) compared with those with neither metabolic syndrome nor diabetes and low CRP levels (reference group) (Fig. 1 (13, 14) , individuals with metabolic syndrome (but without diabetes) have a wide spectrum of risk (15) . Our results demonstrate that those with metabolic syndrome and high CRP levels have at least as high a likelihood of CVD as those with diabetes and low CRP. Our report is unique in examining the relation of metabolic syndrome (without diabetes) and diabetes separately, stratified by CRP levels and in relation to CVD prevalence.
Our cross-sectional results in the U.S. population support findings from Rutter et al. (16) , who recently demonstrated in the Framingham Heart Study that both CRP and metabolic syndrome (inclusive of diabetes) are independent predictors of new CVD events. Also, Ridker et al. (9) prospectively studied 14,710 women, showing those with CRP Ͼ3 mg/l without metabolic syndrome had nearly as great a CVD event incidence as those with the metabolic syndrome and CRP levels Յ3 mg/l and that those with metabolic syndrome who had CRP Ͼ3 mg/l had the worst prognosis. Further, Sattar et al. (17) reported that middle-aged men enrolled in the West of Scotland Coronary Prevention Study with metabolic syndrome and CRP Ͻ3 mg/l had risks of future coronary heart disease events identical to those with no metabolic syndrome and CRP Ͼ3 mg/l, similar to our findings in these groups. The increased risk of coronary heart disease in those with metabolic syndrome and CRP Ͼ3 mg/l was also similar to findings for this group. Our study provides additional data on the clinical significance of elevated CRP levels in the presence of metabolic syndrome (exclusive of those with diabetes) compared with diabetes in relation to CVD, demonstrating that the former have a likelihood of CVD similar to that with those with diabetes who have normal CRP levels. These findings support a recent review suggesting the addition of CRP as a criterion for the diagnosis of metabolic syndrome (18) .
A strength of our study is our U.S. population sample, allowing generalization to the U.S. population. A limitation is the cross-sectional design, allowing us to only make projections to the odds of prevalent CVD. We cannot test whether CVD is the cause, rather than the consequence, of high CRP levels. Finally, it is possible that some of the increased risk seen in those with elevated CRP may be (12) . Our data lend support to the screening of CRP levels in persons with metabolic syndrome, many of whom are at intermediate risk; identification of those with elevated CRP levels may help identify a higher-risk subset of persons with metabolic syndrome who may warrant more intensified risk factor intervention as aggressive as that for those with diabetes (e.g., LDL goals of Ͻ100 mg/dl and blood pressure goals of Ͻ130/80 mmHg). However, clinical trials would be needed in these individuals to document whether there would be actual incremental benefit in prevention of CVD events from treatment to these lower levels.
